Navigation Links
Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax

Single-Dose Protection Observed Prior to or Up to 24 Hours After Exposure to Anthrax

TORONTO, Ontario, May 24, 2007 /PRNewswire/ -- Targanta Therapeutics Corporation announced today the results from a recent study demonstrating oritavancin as a potential therapy for treating exposure to Bacillus anthracis, the bacterium which causes anthrax, an acute infectious disease. Oritavancin, a novel semi- synthetic lipoglycopeptide antibiotic for the treatment of serious gram- positive infections, is Targanta's lead product currently in post-Phase 3 clinical development. This research was conducted and presented in partnership with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) at the American Society for Microbiology (ASM) 107th Annual General Meeting in Toronto, Ontario from May 21-25, 2007.

"We are encouraged by the research demonstrating that oritavancin may represent a potential treatment for anthrax exposure," said Thomas Parr, Ph.D., Chief Scientific Officer, Targanta Therapeutics. "This research eventually could lead to better protection for both military personnel and citizens against an anthrax attack."

Study Methods and Results:

Efficacy of Oritavancin in a Murine Model of Bacillus anthracis Spore Inhalation Anthrax

Using an aerosol-anthrax mouse model, researchers investigated oritavancin (ORI) as potential therapy for inhalational anthrax (post-exposure). In the model, mice were exposed to spores of the Ames strain of B. anthracis at seventy five times the lethal dose necessary to kill 50% of untreated mice (75 x LD50). The control group received either saline or 30 mg/kg of ciprofloxacin (CIP) intraperitoneally (within the abdominal cavity) every 12 hours for 14 days. ORI doses ranged from 0.1 to 30 mg/kg intraperitoneally every 48 hours for 14 days. Alternatively, ORI was administered intravenously from 5 to 50 mg/kg as a single intravenous dose. All
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:8/28/2015)... Aug. 28, 2015  Today, in final recognition of ... Lens Health Week, 1-800 Contacts is sharing how to ... contact lens wearers who do not properly care for ... eye infections. Most contact lens wearers ... a clean lens case is sometimes overlooked.  When proper ...
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... 2015 Perrigo Company plc ("Perrigo") (NYSE: ... ("Mylan") (NASDAQ: MYL ) shareholder vote regarding its ... views of Mylan,s offer to Perrigo shareholders have always ... Board,s careful reflection of the value available to Perrigo ... that Mylan has allowed its shareholders to consider," said ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
... WELLESLEY HILLS, Mass., Aug. 25 Joseph F. ... Spherics, Inc. ("Spherics") for,the benefit of creditors, announced ... at a sealed bid auction on October 10,2008., ... Levodopa-Carbidopa that,is the current gold standard treatment for ...
... Development Studies ... Planned, COPENHAGEN, ... ofatumumab in chronic lymphocytic,leukemia and non-Hodgkin,s lymphoma., Genmab A/S (OMX: GEN) ... (CLL) and follicular,non-Hodgkin,s lymphoma (NHL) this year., "Genmab and GSK have ...
Cached Medicine Technology:Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels 2Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products International ( http://www.nutricompany.com ... of global cosmeceutical and skin care brands. Mr. Fernandez comes with a ... years working in operations, purchasing and management for some of the nations biggest ...
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College President ... the college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who has served ... college expand its reach and impact through innovative technologies and strategies. , “I am ...
(Date:8/29/2015)... ... ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the Director of Policy and Prevention ... educational program titled “Asbestos and Your Health.” , The two and one half hour ... at Calvary United Methodist Church, 16 E Park Ave., Ambler, PA 19002. , This ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made possible ... lives of patients, according to a newly published report. Surviving Mesothelioma has more ... article. , The authors of the new paper focus on several types ...
(Date:8/29/2015)... ... ... Next weekend is Labor Day weekend, the last bash of the season ... year). For IT security personnel, it should also mark the perfect time to make ... than a simple headache. , Joe Caruso, founder and CEO-CTO of Global Digital ...
Breaking Medicine News(10 mins):Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
... the age of 70 suffers from dementia, according to the ... women from all regions of the country. , About 3.4 ... and older, have some form of dementia, the study found. ... from five percent of those aged 71 to 79 to ...
... California will simultaneously open their doors Wednesday to ... cover the,festivities, SAN FRANCISCO, Oct. 30 It,s ... Nurse administrators don,t often,see miniature witches and 3-foot-tall bumblebees, ... 80-year-young ballerinas! But at more,than 150 nursing homes in ...
... their doors,Wednesday to Trick or Treaters and the media ... 30 It,s not every day,pirates and gypsies visit ... and 3-foot tall bumblebees, and little goblins rarely,get to ... 150 nursing homes in California this Halloween, it,s going ...
... Oct. 30 Mylan Inc. (NYSE: MYL ),today ... Vice,President and Global General Counsel. As Global General Counsel, ... the provision of,legal services, counsel and advice globally to ... across the Company. Mr. Haggerty joins Mylan from ...
... good responses in almost half of patients, study found , ... axitinib shows promise for treating people with what,s known as ... typically have a poor response to drug treatment. , Axitinib ... endothelial growth factor receptors 1, 2 and 3. , ...
... Year EPS Outlook for One-time Tax Benefit, CINCINNATI, ... PG ) announced net sales growth of eight ... delivered,mid-single digit or higher sales growth. Organic sales were ... four to six percent target,growth range. The Fabric & ...
Cached Medicine News:Health News:1 in 7 Americans over age 70 has dementia 2Health News:1 in 7 Americans over age 70 has dementia 3Health News:1 in 7 Americans over age 70 has dementia 4Health News:Halloween Events in the Bay Area Bring Young and Old Together for a Ghoulish Good Time 2Health News:Halloween Events in Eureka, California Bring Young and Old Together for a Ghoulish Good Time 2Health News:Mylan Announces Appointment of Joseph F. Haggerty as Senior Vice President and Global General Counsel 2Health News:New Drug Promising Against Tough-to-Treat Kidney Cancer 2Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 2Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 3Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 4Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 5Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 6Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 7Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 8Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 9Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 10Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 11Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 12Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 13Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 14Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 15Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 16
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: